AKAlexandr V Kostarev

Alexandr V Kostarev

*This is an algorithmically generated author record based on publicly available information.

Alexandr V Kostarev has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overcoming of doxorubicin resistance in breast cancer cells by cationic peptides

    by Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova

    Background: Acquired resistance to various drugs is an obstacle to anticancer therapy. Doxorubicin (Dox) is the first-line chemo-drug for therapy of various malignant tumors but it fails when treatment of multi-drug resistant tumors. One of the main factors of Dox-resistance is overexpression of drug resistance genes, particularly, P-glycoprotein – Pgp. Earlier we’ve revealed a high selective apoptosis of tumor cells, induced by some cationic peptides (CPs) in vitro through inactivation their cell targets – chaperone proteins nucleolin/NCL and nucleophosmin/NPM. This paper describes effect of CPs on breast cancer (BC) cell lines HBL 100 and doxorubicin-resistant cell line HBL-100/Dox. Objective: Is to examine the viability of BC and Dox-resistant BC cells after incubation with some CPs. Results: Some Arg/Lys-enriched cationic peptides under study induce cell death by nucleolar stress mechanisms both in HBL 100 BC cell line and HBL 100/ID 120 one. So, this CPs is perspective agents for inducing apoptosis of BC cells and overcoming Dox resistance.